Global Leukapheresis Market Report 2022: Leukapheresis for Pediatric Patients Gaining Ground & Opening Avenues for Growth

News provided by

Nov 09, 2022, 13:15 ET

DUBLIN, Nov. 9, 2022 /PRNewswire/ -- The "Leukapheresis Market by Product (Devices, Filters, Membrane Separators), Leukopak (Mobilized, Non-Mobilized), Indication (ALL, NHL, Multiple Myeloma), Application (Research, Therapeutic), End User (Hospitals, Pharma, Biotech) - Global Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.

The global leukapheresis market is projected to reach USD 98 Million by 2027 from USD 65 Million in 2022, at a CAGR of 8.5%. The global leukopaks market is projected to reach USD 784 Million by 2027 from USD 146 Million in 2022, at a CAGR of 39.8%. Due to the cases of leukaemia rising globally, and the rising need for leukopaks in clinical trials and other research applications, the leukapheresis market is expected to grow in the forecast period.

By application, research applications was the larger segment in the leukapheresis products market in 2021.

By, application, the leukapheresis market is segmented into research applications and therapeutic applications. The research applications segment accounted for the larger share of the leukapheresis products market in 2021. The growing development of cell-based immunotherapies and rising demand for leukapheresis-derived primary cells in drug development are some of the major factors driving the growth of the leukapheresis products market during the forecast period.

Among end users, the academic & research institutes segment accounted for the largest share of the leukopaks market in 2021.

By end user, the leukopaks market is segmented into academic & research institutes, pharmaceutical & biotechnology companies, and contract research organizations. In 2021, the academic & research institutes segment accounted for the largest share of the leukapheresis products market. The increasing number of industry-academic partnerships for conducting research on cell-based cancer therapies are driving the growth of this end-user segment.

In 2021, North America accounted for the largest regional market for leukopaks market

This can be attributed to the presence of a large number of leukopak manufacturing companies in the region, and easy accessibility to technologically advanced blood separation devices, among other factors. The Asia Pacific region is expected to be the fastest-growing region in the forecast period. The increasing CAR-T cell therapy research and the rising number of pharma & biotech companies and research institutes in China are some of the factors driving the market growth.

Market Dynamics

Drivers

Rising Incidence and Prevalence of Leukemia
Increasing Number of Blood Donations
Increased Demand for Leukopaks in Clinical Research

Restraints

High Cost of Therapeutic Leukapheresis and Leukopaks
Stringent Donor Recruitment Criteria
Dearth of Skilled Professionals and Low Adoption of Therapeutic Leukapheresis
Complications Associated with Therapeutic Leukapheresis
Long Procedural Time for Leukapheresis
High Cost of Cellular Immunotherapies and Lack of Favorable Reimbursement

Opportunities

Leukapheresis for Pediatric Patients
Emerging Economies with Investments from Academic Institutes, Pharma-Biotech Companies, and Leading Players
Gaps in Current Leukapheresis Technologies

Challenges

Blood Transfusion Safety in Emerging Countries

Key Topics Covered:

1 Introduction

2 Research Methodology

3 Executive Summary

4 Premium Insights

5 Market Overview

6 Leukapheresis Products Market, by Type

7 Leukapheresis Products Market, by Application

8 Leukapheresis Products Market, by End-user

9 Leukopaks Market, by Type

10 Leukopaks Market, by Indication

11 Leukopaks Market, by End-user

12 Leukapheresis Market, by Region

13 Competitive Landscape

14 Company Profiles

15 Appendix

Companies Mentioned

Accegen
Asahi Kasei Corporation
Beijing Zksk Technology Co. Ltd.
Bioivt
Caltag Medsystems Limited
Charles River Laboratories International, Inc.
Discovery Life Sciences, Inc.
First Choice Bio LLC
Fresenius SE & Co. KGaA
Guangzhou Daji Medical Science and Technology Co. Ltd.
Haemonetics Corporation
Intelligent Tissue Group
Lonza Group AG
Macopharma SA
Medica Spa.
Miltenyi Biotec
Nikkiso Co. Ltd.
Pall Corporation
Precision for Medicine, Inc.
Puriblood Medical Co. Ltd.
Sb-Kawasumi Laboratories, Inc.
Stemexpress, LLC
Terumo BCT
Trina Bioreactives AG
Zenbio, Inc.

For more information about this report visit https://www.researchandmarkets.com/r/d8e82q

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets